UK biotech firm Cytospire Therapeutics has closed an oversubscribed £61 million Series A financing round. Led by 4BIO Capital, the funding will propel the company's innovative cancer immunotherapies into clinical development. The investment specifically targets the advancement of its lead program, CYT X300, for treating solid tumors.
A New Approach to Cancer Immunotherapy
Cytospire is developing a new class of multispecific immune cell engager antibodies. These therapies are engineered to enhance and direct the body's immune system to fight cancer. The company's platform builds on the growing scientific understanding of gamma delta T cells in anti-cancer immune responses.
The company's novel pan-gamma delta T cell engagers aim to solve the efficacy and safety issues of conventional therapies. Unlike traditional approaches, Cytospire’s technology targets all gamma delta T cell subtypes. This strategy is designed to overcome patient heterogeneity and generate a more powerful anti-tumor effect.
Advancing the Clinical Pipeline
The new capital will accelerate the development of Cytospire's lead candidate, CYT X300. This funding will support crucial IND-enabling preclinical studies and the complex GMP manufacturing process. These steps are essential preparations for moving the promising therapy into human clinical trials.
A primary objective for the company is to initiate a first-in-human clinical study for CYT X300. The trial will evaluate the treatment's potential in patients with EGFR-positive solid tumors. These cancers include difficult-to-treat indications like colorectal, head and neck, and non-small cell lung cancers.
A Strong Syndicate of Investors
The financing round was led by 4BIO Capital and drew support from a strong syndicate of specialist investors. Major new participants include Servier Ventures, Sound Bioventures, and Criteria Bio Ventures. Existing investors Abingworth and LifeArc Ventures also reaffirmed their commitment by participating in the round.
This round is distinguished by a £12 million investment from the British Business Bank and marks the first investment from Servier's new corporate venture fund. The diverse backing highlights widespread confidence in Cytospire's scientific approach. Other new investors include Modi Ventures, Medical Incubator Japan, and Pathway Bioventures.
Leadership and Vision for the Future
Natalie Mount, CEO of Cytospire, emphasized the significance of the investor support for their novel approach. She noted that the company is leveraging data showing gamma delta T cells are critical for anti-cancer immunity. This funding validates the quality of the company's science and its dedicated team.
Owen Smith, a partner at 4BIO Capital, commented on the ongoing need for more effective cancer immunotherapies. He expressed pride in leading the strong investor syndicate and excitement for the company's clinical progression. The ultimate goal is to advance Cytospire's portfolio to improve patient outcomes.
In connection with the financing, Cytospire has strengthened its Board of Directors with several key appointments. Alexis Vandier of Servier Ventures, Carmine Circelli of the British Business Bank, and Anna Gran of Sound Bioventures will join the board. Their expertise will guide the company as it transitions into a clinical-stage organization.
This £61 million investment marks a pivotal moment for Cytospire Therapeutics, providing the resources to advance its pioneering therapies. The funding positions the company to enter clinical trials and emerge as a leader in next-generation immune cell engagers. This development offers new hope for patients battling challenging solid tumors.